for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cerecor Inc

CERC.OQ

Latest Trade

4.23USD

Change

0.05(+1.20%)

Volume

14,079

Today's Range

4.04

 - 

4.23

52 Week Range

2.91

 - 

7.58

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
4.18
Open
4.16
Volume
14,079
3M AVG Volume
1.22
Today's High
4.23
Today's Low
4.04
52 Week High
7.58
52 Week Low
2.91
Shares Out (MIL)
44.11
Market Cap (MIL)
169.37
Forward P/E
-9.97
Dividend (Yield %)
--

Next Event

Q4 2019 Cerecor Inc Earnings Release

Latest Developments

More

Cerecor Reports Qtrly Loss Per Share $0.07

Cerecor Announces Clinical Updates On CERC-301 And CERC-802

Cerecor Files For Resale Of Up To 2.2 Million Shares Of Its Common Stock

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cerecor Inc

Cerecor, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment. The Company owns the rights to its COMTi platform. Catechol O methyltransferase (COMT) is an enzyme critical for the inactivation and metabolism of dopamine and its inhibition in the brain has applicability in treating subjects with neuropsychiatric conditions, including MDD, schizophrenia, Parkinson's disease and pathological gambling. Its COMTi platform comprises COMT inhibitors with selectivity for membrane bound COMT, which is the dominant form of COMT.

Industry

Biotechnology & Drugs

Contact Info

540 Gaither Rd Ste 400

+1.410.5228707

http://www.cerecor.com

Executive Leadership

Simon C. Pedder

Executive Chairman of the Board

Mike Cola

Chief Executive Officer

Joseph M. Miller

Chief Financial Officer, Principal Executive Officer and Principal Financial Officer

Jamie A. Harrell

Executive Vice President - Marketing, External Communications

Pericles Calias

Chief Scientific Officer and Head of Research & Development

Key Stats

1.67 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-1.870

2018

-1.200

2019(E)

-0.207
Price To Earnings (TTM)
--
Price To Sales (TTM)
8.28
Price To Book (MRQ)
9.30
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
83.99
LT Debt To Equity (MRQ)
78.23
Return on Investment (TTM)
-56.28
Return on Equity (TTM)
-37.26

Latest News

Latest News

BRIEF-Cerecor Q4 Loss Per Share $0.11

* REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2017

BRIEF-Cerecor Inc Appoints Peter Greenleaf CEO

* CERECOR APPOINTS PETER GREENLEAF AS CHIEF EXECUTIVE OFFICER

BRIEF-Cerecor To Acquire Avadel Pharmaceuticals' Pediatric Assets

* CERECOR TO ACQUIRE AVADEL PHARMACEUTICALS' PEDIATRIC ASSETS

BRIEF-Cerecor announces leadership changes

* Cerecor Inc - Interim Chief Executive Officer John Kaiser and Chief Medical Officer Dr. Ronald Marcus stepping down

BRIEF-Cerecor acquires TRX Pharmaceuticals

* Cerecor Inc - Under terms of transactions, Cerecor will make an initial payment of $23 million for purchase of TRX

BRIEF-Cerecor reports Q3 earnings per share of $0.52

* As of Sept 30, cash and cash equivalents were $24.0 million, escrowed cash receivable was $3.75 million and current liabilities were $4.8 million

BRIEF-Cerecor Inc says Uli Hacksell retires as CEO, president

* Cerecor Inc announces retirement of Dr. Uli Hacksell as president and chief executive officer

BRIEF-Cerecor Inc Q2 loss per share $0.14

* In August 2017, co sold its world-wide rights of CERC-501 to Janssen in exchange for an initial payment of $25 million

BRIEF-Cerecor files for resale from time to time of up to 29.2 mln shares

* Files for resale from time to time of up to 29.2 million shares of its common stock - SEC filing

BRIEF-Cerecor appoints Steven Boyd and Peter Greenleaf to board of directors

* Cerecor appoints Steven Boyd and Peter Greenleaf to board of directors Source text for Eikon: Further company coverage:

BRIEF-Cerecor Q1 loss per share $0.19

* Cerecor inc - completed a private offering with armistice capital that should support company's operations through 2017 Source text for Eikon: Further company coverage:

BRIEF-Cerecor reports topline data from a NIH sponsored proof-of-concept trial of CERC-501 in treatment-resistant depression

* Cerecor reports encouraging topline data from a NIH sponsored proof-of-concept trial of Cerc-501 in treatment-resistant depression

BRIEF-CERECOR ENGAGES SUNTRUST ROBINSON HUMPHREY TO ASSIST WITH REVIEW OF STRATEGIC ALTERNATIVES

* CERECOR ENGAGES SUNTRUST ROBINSON HUMPHREY TO ASSIST WITH REVIEW OF STRATEGIC ALTERNATIVES

BRIEF-Cerecor announces at-the-market equity offering program

* Intends to use net proceeds from at--market offering program, to partially fund research and development of CERC-501 and CERC-611

BRIEF-Cerecor reports top-line data from CERC-301 Phase 2 study

* Cerecor reports top-line data from CERC-301 Phase 2 study for major depressive disorder

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up